JNJ.DE Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 17:35):

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide...

Stats
Tagesvolumen	3 900.00
Durchschnittsvolumen	3 222.00
Marktkapitalisierung	328.50B
EPS	€0 ( 2024-04-15 )
Nächstes Ertragsdatum	( €0 ) 2024-07-16
Last Dividend	€1.190 ( 2023-08-25 )
Next Dividend	€0 ( N/A )
P/E	19.64
ATR14	€0.140 (0.10%)

Volumen Korrelation

Lang: 0.01 (neutral)

Kurz: 0.21 (neutral)

Signal:(53.523) Neutral

Johnson & Johnson Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Johnson & Johnson Korrelation - Währung/Rohstoff

-0.32
( neutral )

-0.21
( neutral )

-0.36
( neutral )

-0.18
( neutral )

0.66
( moderate )

Johnson & Johnson Finanzdaten

Annual	2023
Umsatz:	€85.16B
Bruttogewinn:	€58.61B (68.82 %)
EPS:	€13.88

FY	2023
Umsatz:	€85.16B
Bruttogewinn:	€58.61B (68.82 %)
EPS:	€13.88

FY	2022
Umsatz:	€94.94B
Bruttogewinn:	€63.85B (67.26 %)
EPS:	€6.86

FY	2021
Umsatz:	€93.78B
Bruttogewinn:	€63.92B (68.16 %)
EPS:	€7.93

Financial Reports:

No articles found.

Johnson & Johnson Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€1.130 (N/A)	€1.130 (N/A)	€1.130 (N/A)	€1.190 (N/A)	€1.190 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Johnson & Johnson Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 3.76 - low (25.10%) | Divividend Growth Potential Score: 5.83 - Stable (16.53%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€0.415	2008-02-22
Last Dividend	€1.190	2023-08-25
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	65	--
Total Paid Out	€56.18	--
Avg. Dividend % Per Year	0.00%	--
Score	3.59	--
Div. Sustainability Score	3.76
Div.Growth Potential Score	5.83
Div. Directional Score	4.79	--

Next Divdend (Est)
(2024-07-01)

€1.211 Estimate 22.50 %

Dividend Stability

0.60 Above Average

Dividend Score

3.59

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
ORC.DE	Ex Dividend Knight	2023-10-11	Quarterly	0.00%
AOMD.DE	No Dividend Player	2023-07-17	Sporadic	0.00%
HBH.DE	Ex Dividend Junior	2023-07-10	Annually	0.00%
RNL.DE	Ex Dividend Junior	2023-05-17	Sporadic	0.00%
BYW6.DE	Ex Dividend Junior	2023-06-07	Annually	0.00%
KBX.DE	Ex Dividend Knight	2023-05-08	Annually	0.00%
THYG.F	Ex Dividend Junior	2023-08-21	Semi-Annually	0.00%
DGR.DE	Ex Dividend Junior	2023-06-28	Annually	0.00%
MRK.DE	Ex Dividend Knight	2023-05-02	Annually	0.00%
5Y7.F	Ex Dividend Knight	2023-08-08	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.453	1.500	0.949	1.424	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.572	1.500	4.76	7.14	[0.1 - 1]
payoutRatioTTM	0.218	-1.000	7.82	-7.82	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	44.51	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	8.03	2.00	7.32	10.00	[0 - 30]
freeCashFlowPerShareTTM	6.32	2.00	6.84	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.687	1.000	1.890	1.890	[0.2 - 0.8]
operatingProfitMarginTTM	0.273	1.000	6.54	6.54	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				3.76

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	8.71	1.000	9.22	0	[1 - 100]
returnOnEquityTTM	0.572	2.50	6.63	7.14	[0.1 - 1.5]
freeCashFlowPerShareTTM	6.32	2.00	7.89	10.00	[0 - 30]
dividendYielPercentageTTM	3.28	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	8.03	2.00	7.32	10.00	[0 - 30]
payoutRatioTTM	0.218	1.500	7.82	-7.82	[0 - 1]
pegRatioTTM	-0.301	1.500	-5.34	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.218	1.000	7.05	0	[0.1 - 0.5]
Total Score				5.83

Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.